high-dose riboflavin (10 mg kg 1 day 1 ) or flavin esters rapidly restore ATP production and cell viability in vitro ( SLC52A3 knock-down and SLC52A3 / mice recapitulate hearing loss, ataxia and early death, all of which improve with systemic riboflavin supplementation ( SLC52A2 gene replacement normalized FMN/FAD levels, rescued spinal motor neurons and reversed motor deficits when delivered pre-symptomatically, underscoring the feasibility of curative therapy ( Clinically, oral or intravenous riboflavin remains first-line treatment
A number of studies were conducted but using intravenous or nebulized GSH
Except for anti-IGF-IR or anti-IGF1/2 mAbs, many small-molecule IGF-IR inhibitors have been developed [158,159,160,161,162,163]
Therefore, amino acid metabolism is closely linked to the regulation of cellular iron dependent death
No human study has confirmed this happens at commercially used oral doses